These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
702 related articles for article (PubMed ID: 33157066)
61. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays. DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791 [TBL] [Abstract][Full Text] [Related]
62. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]
63. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma. Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688 [TBL] [Abstract][Full Text] [Related]
64. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160 [TBL] [Abstract][Full Text] [Related]
65. Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay. Mousa ZS; Abdulamir AS Arch Razi Inst; 2022 Feb; 77(1):391-402. PubMed ID: 35891753 [TBL] [Abstract][Full Text] [Related]
66. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds. Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939 [TBL] [Abstract][Full Text] [Related]
67. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies. Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781 [TBL] [Abstract][Full Text] [Related]
68. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619 [TBL] [Abstract][Full Text] [Related]
69. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648 [TBL] [Abstract][Full Text] [Related]
70. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations. Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595 [TBL] [Abstract][Full Text] [Related]
73. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
74. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710 [TBL] [Abstract][Full Text] [Related]
75. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972 [TBL] [Abstract][Full Text] [Related]
76. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma. Wang L; Zhao J; Nguyen LNT; Adkins JL; Schank M; Khanal S; Nguyen LN; Dang X; Cao D; Thakuri BKC; Lu Z; Zhang J; Zhang Y; Wu XY; El Gazzar M; Ning S; Moorman JP; Yao ZQ Sci Rep; 2021 Mar; 11(1):5558. PubMed ID: 33692386 [TBL] [Abstract][Full Text] [Related]
77. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related]
78. Resistance of SARS-CoV-2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020. Drews SJ; Abe KT; Hu Q; Samson R; Gingras AC; Colwill K; Rathod B; Wang J; Fazel-Zarandi M; Yi QL; Robinson A; Wood H; Tuite A; Fisman D; Evans DH; Lin YJ; O'Brien SF Transfusion; 2022 Jan; 62(1):37-43. PubMed ID: 34662434 [TBL] [Abstract][Full Text] [Related]
79. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334 [TBL] [Abstract][Full Text] [Related]
80. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG Front Immunol; 2020; 11():628971. PubMed ID: 33584731 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]